Table 3 Associations of single acylcarnitines and combined indexes with baseline eGFR
From: Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy
Name | Association with baseline eGFR | ||
|---|---|---|---|
β | SE | P | |
Free carnitine (C0) | −0.21 | 0.11 | 0.110108011 |
Acetylcarnitine (C2) | −0.36 | 0.1 | 0.001989281 |
Butyrylcarnitine (C4) | −0.63 | 0.08 | 7.42E-10 |
semi Tiglyl-carnitine (C5:1) | −0.56 | 0.09 | 4.10E-07 |
Valerylcarnitine (C5) | −0.37 | 0.11 | 0.002867891 |
semi Octanenoylcarnitine (C8:1) | −0.46 | 0.1 | 0.00012474 |
Octanoylcarnitine (C8) | −0.13 | 0.11 | 0.333735122 |
Malonylcarnitine (C3DC) | −0.41 | 0.1 | 0.000543281 |
C10:1 | −0.32 | 0.11 | 0.011733593 |
Decanoylcarnitine (C10) | −0.12 | 0.11 | 0.336089636 |
C5DC | −0.65 | 0.08 | 3.01E-10 |
semi Dodecenoylcarnitine (C12:1) | −0.25 | 0.1 | 0.041281611 |
Dodecanoylcarnitine (C12) | −0.19 | 0.11 | 0.147639204 |
semi 3-Hydroxydodecanoylcarnitne (C12OH) | −0.27 | 0.11 | 0.03221931 |
C14:1 | −0.16 | 0.11 | 0.227662143 |
Myristoylcarnitine (C14) | −0.23 | 0.1 | 0.061749229 |
semi (C16:2) | −0.26 | 0.1 | 0.035592205 |
semi Palmitoleylcarnitine (C16:1) | − 0.25 | 0.1 | 0.04354928 |
Palmitoylcarnitine (C16) | −0.16 | 0.11 | 0.227662143 |
semi Sebacylcarnitine (C10DC) | −0.12 | 0.11 | 0.366303947 |
semi Linoleylcarnitine(C18:2) | −0.06 | 0.11 | 0.641083979 |
semi Oleylcarnitine (C18:1) | −0.06 | 0.11 | 0.641083979 |
semi Stearoylcarnitine (C18) | −0.11 | 0.11 | 0.410468226 |
semi C12DC | −0.12 | 0.11 | 0.353100378 |
semi 3-Hydroxylinoleyl(C18:2OH) | 0.05 | 0.11 | 0.682991111 |
semi 3-Hydroxystearoylcarnitine (C18OH) | −0.08 | 0.11 | 0.53159956 |
semi Arachidoylcarnitine (C20) | −0.13 | 0.11 | 0.333735122 |
Short-chain Acylcarnitine | −0.13 | 0.05 | 0.028647383 |
Medium-chain Acylcarnitine | −7.66 | 1.88 | 0.000543281 |
Long-chain Acylcarnitine | −0.19 | 0.77 | 0.800766318 |